We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Acadia Pharma Gets FDA Complete Response Letter for Anti-Psychosis Drug Nuplazid
Acadia Pharma Gets FDA Complete Response Letter for Anti-Psychosis Drug Nuplazid
The FDA has issued a Complete Response Letter (CRL) to San Diego, Calif.-based Acadia Pharmaceuticals for their supplemental New Drug Application for Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP).